SpringWorks Therapeutics (NASDAQ:SWTX) Earns Buy Rating from Analysts at Goldman Sachs Group

Goldman Sachs Group began coverage on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a report issued on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $37.00 target price on the stock.

A number of other equities analysts have also weighed in on the company. Wedbush started coverage on SpringWorks Therapeutics in a research report on Tuesday. They set an outperform rating and a $33.00 target price on the stock. Cowen started coverage on SpringWorks Therapeutics in a research report on Tuesday. They set an outperform rating on the stock. Finally, JPMorgan Chase & Co. started coverage on SpringWorks Therapeutics in a research report on Tuesday. They set an overweight rating and a $32.00 target price on the stock.

Shares of SWTX opened at $18.96 on Tuesday. SpringWorks Therapeutics has a 52-week low of $17.66 and a 52-week high of $28.62.

In other news, major shareholder Bain Capital Life Sciences Inv bought 150,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, with a total value of $2,700,000.00. Also, Director Stephen P. Squinto bought 275,000 shares of the stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $4,950,000.00.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Story: Call Option Volume

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.